Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Mayo Clinic discovers REM Sleep Behavior Disorder is linked with Parkinson's disease

Mayo Clinic : 16 April, 2008  (Company News)
The findings from three new research studies carried out by the Mayo Clinic has discovered that REM (rapid eye movement) sleep behaviour disorder is associated with anxiety, apathy, lower scores in attention and executive functioning, as well as symptoms of Parkinson's disease.
People who have REM sleep behaviour disorder (RBD) appear to act out their dreams, which often are unpleasant and violent. Acting out is caused by a loss of normal muscle paralysis in REM sleep, the stage of sleep when dreaming occurs. A relatively uncommon condition, RBD is estimated to affect approximately 0.5 percent of the population, but occurs most frequently in older males.

'Previous studies have shown that some patients with RBD subsequently develop dementia and/or parkinsonism, which typically reflects a neurodegenerative disorder such as Lewy body dementia or Parkinson's disease,' said Bradley Boeve, MD, an author of these studies and a neurologist at Mayo Clinic. 'Our knowledge on the RBD-neurodegenerative disease association is largely based on studies focused on single patients, or small groups of patients, with RBD. There are very few studies that have been carried out on RBD on a large scale. Plus, we currently aren't able to identify which patients with RBD will later develop other features of a neurodegenerative disease and which patients with RBD will not. We therefore sought to study RBD and other features commonly associated with Lewy body dementia and Parkinson's disease in a large population-based study.'

Dr Boeve and a team of Mayo Clinic physicians set out to determine whether cognitively-normal individuals with RBD have other features commonly associated with Lewy body dementia and Parkinson's disease. They identified 765 individuals, ages 70 to 89, who underwent a battery of scales and tests. Using the Mayo sleep questionnaire, a validated screening measure for RBD, researchers determined that 8 percent of these individuals had probable RBD.

Twenty-one percent with probable RBD had anxiety and 11.5 percent had apathy (compared with eight percent and four percent, respectively, for individuals without RBD).

Those individuals with RBD had significantly lower scores on neuropsychological measures of attention and executive functioning, such as concentration, decision making, and higher-order problem solving. Additionally, researchers found that 1.8 percent of the individuals had both RBD and parkinsonism.

'There is currently no treatment to delay the onset or prevent dementia or parkinsonism in patients with RBD who are destined to develop these neurologic problems in the future,' said Dr Boeve. 'Our ultimate goal is to use therapies that would delay the onset or prevent these problems from ever developing in patients who have a form of RBD that reflects an evolving neurodegenerative disease. However, much more research is needed to get to that point.'

The findings were presented at the American Academy of Neurology Annual Meeting in Chicago on April 15, 2008.

Dr Boeve and his team will continue to study this group of patients to better understand how RBD is associated with neurodegenerative disease. Other members of the Mayo Clinic research team included Jennifer Molano, MD, Ebru Mihci, MD, Rosebud Roberts, MBChB, Yonas Geda, MD, David Knopman, MD, Eric Tangalos, MD, Glenn Smith, PhD, Robert Ivnik, PhD, Ruth Cha, V Shane Pankratz, PhD, Michael Silber, MBChB, Tanis Ferman, PhD, and Ronald Petersen, MD, PhD.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo